First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: NeoGenomics: the story is balanced — Clinical test volume trends and requisition growth rates, particularly advanced molecular testing (NGS panels…
★ Analysts see FY2026 revenue reaching $800M — +10.1% growth in a single year.
What Moves the Stock
1Clinical test volume trends and requisition growth rates, particularly advanced molecular testing (NGS panels, liquid biopsy) which drive higher revenue per requisition
2Medicare reimbursement policy changes and CMS rate updates for molecular diagnostic codes (81455, 81479, 0245U series)
3Pharma services contract wins and clinical trial activity levels in oncology drug development pipeline
4Operating margin trajectory and progress toward breakeven EBITDA, including cost reduction execution and lab consolidation milestones
5Competitive dynamics with larger reference labs (Quest, LabCorp) expanding oncology capabilities and specialized competitors (Guardant, Foundation Medicine) in liquid biopsy
6Clinical testing services (~85-90% of revenue): Oncology-focused diagnostic tests billed to Medicare, commercial payers, and hospitals on per-test basis
7Pharma services (~10-15% of revenue): Clinical trial support and companion diagnostics for pharmaceutical and biotech companies developing cancer therapeutics
8International operations: European laboratory services through Swiss subsidiary, representing smaller but growing revenue contribution
value/turnaround - The 0.4x price/sales and 0.3x price/book valuation attracts deep value investors betting on operational restructuring…
Rising rates create moderate headwinds through two channels: (1) Higher cost of capital for growth investments and potential refinancing…
Watch on earnings: Monthly clinical test requisition volumes and year-over-year growth rates by test category (molecular, flow cytometry, IHC), Average revenue per clinical requisition trending toward $350-400 range indicating favorable mix shift to advanced molecular tests, Adjusted EBITDA margin progression toward breakeven and management's $40-50M cost reduction program milestones.
One Sentence Summary:
NeoGenomics: the story is balanced — clinical test volume trends and requisition growth rates, particularly advanced molecular testing (ngs panels.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.